NO963186L - Neurobeskyttende kromanforbindelser - Google Patents

Neurobeskyttende kromanforbindelser

Info

Publication number
NO963186L
NO963186L NO963186A NO963186A NO963186L NO 963186 L NO963186 L NO 963186L NO 963186 A NO963186 A NO 963186A NO 963186 A NO963186 A NO 963186A NO 963186 L NO963186 L NO 963186L
Authority
NO
Norway
Prior art keywords
pct
neuroprotective
chromium compounds
sec
date
Prior art date
Application number
NO963186A
Other languages
English (en)
Other versions
NO963186D0 (no
NO309190B1 (no
Inventor
Todd W Butler
Bertrand Leo Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO963186D0 publication Critical patent/NO963186D0/no
Publication of NO963186L publication Critical patent/NO963186L/no
Publication of NO309190B1 publication Critical patent/NO309190B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO963186A 1994-01-31 1996-07-30 Neurobeskyttende kromanforbindelser og farmasöytisk blanding NO309190B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31
PCT/IB1994/000365 WO1995020587A1 (en) 1994-01-31 1994-11-21 Neuroprotective chroman compounds

Publications (3)

Publication Number Publication Date
NO963186D0 NO963186D0 (no) 1996-07-30
NO963186L true NO963186L (no) 1996-07-30
NO309190B1 NO309190B1 (no) 2000-12-27

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963186A NO309190B1 (no) 1994-01-31 1996-07-30 Neurobeskyttende kromanforbindelser og farmasöytisk blanding

Country Status (27)

Country Link
US (1) US5744483A (no)
EP (1) EP0741724B1 (no)
JP (1) JP2866743B2 (no)
CN (1) CN1048247C (no)
AT (1) ATE183184T1 (no)
AU (1) AU684568B2 (no)
BR (2) BR9408506A (no)
CA (1) CA2182101C (no)
CO (1) CO4230161A1 (no)
CZ (1) CZ286757B6 (no)
DE (1) DE69420053T2 (no)
DK (1) DK0741724T3 (no)
EG (1) EG20672A (no)
ES (1) ES2134361T3 (no)
FI (1) FI113769B (no)
GR (1) GR3031356T3 (no)
HU (1) HU221633B1 (no)
IL (1) IL112415A (no)
MY (1) MY111623A (no)
NO (1) NO309190B1 (no)
NZ (1) NZ275151A (no)
PE (1) PE43795A1 (no)
PL (1) PL179448B1 (no)
RU (1) RU2126404C1 (no)
TW (1) TW449591B (no)
WO (1) WO1995020587A1 (no)
ZA (1) ZA95692B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859773A1 (en) * 1995-09-15 1998-08-26 Pfizer Inc. Phenol derivatives with pharmaceutical activity
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
JP2009514828A (ja) 2005-11-03 2009-04-09 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (no) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
GB2107706A (en) * 1981-09-25 1983-05-05 Beecham Group Plc Benzopyrans
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
SK279476B6 (sk) * 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
US5744483A (en) 1998-04-28
FI950403A (fi) 1995-08-01
CN1142825A (zh) 1997-02-12
PL179448B1 (pl) 2000-09-29
DE69420053T2 (de) 1999-11-25
HU9602100D0 (en) 1996-09-30
MY111623A (en) 2000-09-27
HU221633B1 (hu) 2002-12-28
ATE183184T1 (de) 1999-08-15
EG20672A (en) 1999-11-30
CZ225696A3 (en) 1997-01-15
CN1048247C (zh) 2000-01-12
EP0741724A1 (en) 1996-11-13
AU684568B2 (en) 1997-12-18
CA2182101A1 (en) 1995-08-03
GR3031356T3 (en) 2000-01-31
DE69420053D1 (de) 1999-09-16
DK0741724T3 (da) 1999-12-20
TW449591B (en) 2001-08-11
NZ275151A (en) 1998-02-26
ZA95692B (en) 1996-07-30
EP0741724B1 (en) 1999-08-11
BR9408506A (pt) 1997-08-05
PL315681A1 (en) 1996-11-25
FI113769B (fi) 2004-06-15
ES2134361T3 (es) 1999-10-01
HUT75942A (en) 1997-05-28
FI950403A0 (fi) 1995-01-30
BR9500380A (pt) 1995-10-17
JP2866743B2 (ja) 1999-03-08
NO963186D0 (no) 1996-07-30
IL112415A (en) 1999-07-14
RU2126404C1 (ru) 1999-02-20
PE43795A1 (es) 1995-12-09
CA2182101C (en) 1999-08-03
AU8066394A (en) 1995-08-15
CO4230161A1 (es) 1995-10-19
NO309190B1 (no) 2000-12-27
IL112415A0 (en) 1995-03-30
JPH09501698A (ja) 1997-02-18
CZ286757B6 (en) 2000-06-14
WO1995020587A1 (en) 1995-08-03

Similar Documents

Publication Publication Date Title
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
NO963186L (no) Neurobeskyttende kromanforbindelser
DK0738147T3 (da) Anvendelse af riluzol ved behandling af mitochondriesygdomme
EP0653936A1 (en) USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE IN THE TREATMENT OF CANCER.
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
EE200100122A (et) R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks